Pigmentation Disorders Treatment Market to Expand at a CAGR of more than 6.8% from 2018 to 2030

The global pigmentation disorders treatment market was valued at around US$ 5,225 Mn in 2017 and is anticipated to expand at a CAGR of more than 6.8% from 2018 to 2026 to reach around US$ 9,268.6 Mn in 2030

Pigmentation Disorders Treatment Market – Snapshot

Pigmentation is coloring. When the color of one’s skin is affected, it is called skin pigmentation disorder. Presence of melanin in skin gives the skin its color. Melanin is made by the special cells in the skin. When these cells become unhealthy or are damaged, it leaves impact on the production of melanin. Some of the pigmentation disorders attack the skin in some patches, whilst others leave undesirable impact on the entire body. Increased occurrences of skin disorders is likely to amplify growth opportunities for the global pigmentation disorders treatment market in the years to come.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111995

An upgradation in the lifestyle of people together with augmented demand for skin lightening is likely to play an important role in propelling growth of the global pigmentation disorders treatment market in the years to come. In addition to that, availability of high disposable income and rise in the aging population is estimated to shoot up the demand for pigmentation disorders treatment.

Some of the common types of pigmentation disorders comprise the below-mentioned

  • Albinism
  • Melasma
  • Vitiligo
  • Post-Inflammatory Hyperpigmentation (PIH)

At present, topical treatment is dominating the global pigmentation disorders treatment market, thanks to the much better clinical outcomes in those patients who are affected with various kinds of pigmentation disorders. L-ascorbic acid, hydroquinone, and azelaic acid are some of the popular topical drugs available widely in the market.

There has been a growing prominence of chemical peels for the purpose of treatment of facial hyper-pigmentation disorders. In this procedure, chemical peels are dipped in chemicals and then are applied on face or on the targeted areas, hands, and neck to remove the dead skin cells. The removal of dead skin the triggers growth of new skin cells on the affected areas.

 Global Pigmentation Disorders Treatment Market – Snapshot

Pigmentation disorders include a large number of heterogeneous conditions that are usually characterized by altered melanocyte density, melanin concentration, or both, and result in altered pigmentation of the skin. Pigmentation disorders are of three types: hypopigmentation, depigmentation, or hyperpigmentation. Areas where pigmentation appears may be focal or diffuse. In hypopigmentation, pigments are decreased, whereas in depigmentation, pigments are completely lost, leaving the skin white. The most common disorders are melasma (hyperpigmentary) and vitiligo (hypopigmentary). The global pigmentation disorders treatment market was valued at around US$ 5,225 Mn in 2017 and is anticipated to expand at a CAGR of more than 6.8% from 2018 to 2026 to reach around US$ 9,268.6 Mn in 2026. Several factors such as augmented adoption of lasers in pigmentation disorders treatment, decrease in social taboos boosting acceptance of pigmentation disorders treatment measures, and increase in prevalence of pigmentation-related disorders are driving the global pigmentation disorders treatment market.

View full report@ https://qyresearchmedical.com/report/pigmentation-disorders-treatment-market-treatment-topical-drugs-laser-therapy-chemical-peels-phototherapy-microdermabrasion-key-disease-indications-hyperpigmentation-melasma-post-inflammatory-hyperpigmen-018-2030/111995

pigmentation disorders treatment market

After stringent restructuring of regulations against dermo-cosmetic products and services, companies have started focussing on efficacy and quality with high investments in R&D. This has ultimately helped boost technological development and emergence of new products, services, and devices in the pigmentation disorder treatment market. The products and services have been moderated by regulatory bodies and have minimal side effects.

Opportunities for introducing new products, services, and devices are high as the market consists of established players and their brands. However, the market is still in search of highly efficient products and portable and technologically advanced devices. Safety and efficacy are major concerns in the pigmentation disorders treatment market. Therefore, introduction of such products presents a window of opportunity for new players to enter the market and establish themselves. The appreciation of regulatory compliance is a major factor that contributes to the success or failure of treatments, thus affecting sales. Galderma launched the triple combination to improve compliance of its key product, Tri-luma. Increased patient and provider awareness is also likely to help increase patient share of many marketed therapies during the forecast period.

The pigmentation disorder treatment market has been segmented based on treatment, disease indication, end-user, and region. In terms of treatment, the topical drugs segment is estimated to account for a prominent share of the market. An increasing number of patients with pigmentation disorders are visiting dermatologists, and topical drugs are being prescribed to these patients. With an existing unmet need for better treatment armamentarium for severe, recalcitrant patients and an estimated drug-treated population that is expected to double over the next decade, topical drugs is an attractive segment for drug developers. This is expected to fuel commercial interest in the development of tropical drugs.

Based on disease indication, the vitiligo and melasma segment constituted a major share of the market in 2017. The segment is likely to expand at a significant growth rate as compared to other disease indication segments during the forecast period. Globally, the prevalence of vitiligo and melasma varies. Women are far more likely to be affected by melisma than men, and both sexes are affected equally by vitiligo. In pigmentation, inadequate patient compliance still remains a significant unmet need. This single factor has hindered the ability of patients to achieve maximum treatment benefit, given the therapeutic options currently available, and has resulted in multiple failed treatment attempts.

In terms of region, the global pigmentation disorder treatment market has been categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The pigmentation disorders treatment market is dominated by Asia Pacific. The market in the region is likely gain market share and expand at a rapid pace during the forecast period. The market in Asia Pacific is likely to be boosted by an increase in population, awareness about pigmentation disorder treatments and products, and growing economies. Furthermore, the pigmentation disorder treatment market in emerging economies of the Middle East, Latin America, and Africa is anticipated to add to the growth of the global market.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111995/2900

Prominent players in the global pigmentation disorder treatment market include Bayer AG, ALLERGAN, Galderma S.A., SkinCeuticals, Pierre Fabre, EpiPharm AG, RXi Pharmaceuticals Corporation, Obagi Cosmeceuticals LLC, and Vivier Pharma. The prevalent trend in the market is the strategic acquisition of key dermatology products by Big Pharma. A notable event in 2009 involved the acquisition of Stiefel, a leading dermatology company, by GSK for US$ 3.6 Bn.

The global pigmentation disorders treatment market has been segmented as follows:

Treatment

  • Topical Drugs
  • Laser Therapy
  • Chemical Peels
  • Microdermabrasion
  • Phototherapy
  • Others

Disease Indication

  • Hypopigmentation
  • Vitiligo
  • Albinism
  • Others
  • Hyperpigmentation
  • Melasma
  • Post-inflammatory Hyperpigmentation
  • Solar Lentigines
  • Others

End-user

  • Hospitals
  • Aesthetic Clinics & Dermatology Centers
  • Others

Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • Australia & New Zealand
  • India
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC
  • South Africa
  • Israel
  • Rest of Middle East & Africa

TABLE OF CONTENT

Section 01 Preface
1.1 Report Scope and Market Segmentation
1.2 Research Highlights

Section 02 Assumptions and Research Methodology
2.1 Assumptions
2.2 Research Methodology

Section 03 Executive Summary
3.1 Global Pigmentation Disorders Treatment Market Size (US$ Mn)
3.2 Global Pigmentation Disorders Treatment Market Snapshot, 2017
3.3 Global Pigmentation Disorders Treatment Market: Opportunity Map

Section 04 Market Overview
4.1 Overview
4.2 Global Pigmentation Disorders Treatment Market Size (US$ Mn) Forecast, 2016–2026
4.3 Global Pigmentation Disorders Treatment Market Outlook
4.4 Global Pigmentation Disorders Treatment Market: Porter’s Five Forces Analysis
4.5 Pigmentation Disorders Treatment Market: Pipeline Analysis
4.6 Key Partnership & Acquisitions
4.7 Policies and Regulations, by Region
4.8 Disease Prevalence and Incidence Rate Globally

Section 05 Market Dynamics
5.1 Drivers
5.2 Restraints
5.3 Opportunity Analysis
5.4 Opportunities
5.5 Trends

Section 06 Pigmentation Disorders Treatment Market Analysis, by Treatment
6.1 Introduction
6.2 Global Pigmentation Disorders Treatment Market Value Share Analysis, by Treatment
6.3 Pigmentation Disorders Treatment Market Analysis, by Treatment
6.3.1 Topical Drugs
6.3.2 Laser Therapy
6.3.3 Chemical Peels
6.3.4 Microdermabrasion
6.3.5 Phototherapy
6.3.6 Others
6.4 Pigmentation Disorders Treatment Market Attractiveness Analysis, by Treatment

Section 07 Pigmentation Disorders Treatment Market Analysis, by Disease Indication
7.1 Introduction
7.2 Global Pigmentation Disorders Treatment Market Value Share Analysis, by Disease Indication
7.3 Pigmentation Disorders Treatment Market Analysis, by Disease Indication
7.3.1 Global Pigmentation Disorders Treatment Market Analysis, by Hypopigmentation
7.3.1.1 Vitiligo
7.3.1.2 Albinism
7.3.1.3 Others
7.3.2 Global Pigmentation Disorders Treatment Market Analysis, by Hyperpigmentation
7.3.2.1 Melasma
7.3.2.2 Post-inflammatory Pigmentation
7.3.2.3 Solar Lentigines
7.3.2.4 Others
7.4 Pigmentation Disorders Treatment Market Attractiveness Analysis, by Disease Indication
7.5 Pigmentation Disorders Treatment Market Attractiveness Analysis, by Hypopigmentation
7.6 Pigmentation Disorders Treatment Market Attractiveness Analysis, by Hyperpigmentation

Section 08 Pigmentation Disorders Treatment Market Analysis, by End-user
8.1 Introduction
8.2 Global Pigmentation Disorders Treatment Market Value Share Analysis, by End-user
8.3 Pigmentation Disorders Treatment Market Analysis, by End-user
8.3.1 Hospitals
8.3.2 Aesthetic Clinics & Dermatology Centers
8.3.3 Others
8.4 Pigmentation Disorders Treatment Market Attractiveness Analysis, by End-user

Section 09 Pigmentation Disorders Treatment Market Analysis, by Region
9.1 Global Pigmentation Disorders Treatment Market Snapshot, by Country
9.2 Global Pigmentation Disorders Treatment Market Value Share Analysis, by Region
9.3 Pigmentation Disorders Treatment Market Forecast, by Region
9.3.1 North America
9.3.2 Europe
9.3.3 Asia Pacific
9.3.4 Latin America
9.3.5 Middle East & Africa
9.4 Pigmentation Disorders Treatment Market Attractiveness Analysis, by Region

Section 10 North America Pigmentation Disorders Treatment Market Analysis
10.1 Key Findings
10.2 North America Pigmentation Disorders Treatment Market Overview
10.3 North America Market Value Share Analysis, by Treatment
10.4 North America Market Forecast, by Treatment
10.4.1 Topical Drugs
10.4.2 Laser Therapy
10.4.3 Chemical Peels
10.4.4 Microdermabrasion
10.4.5 Phototherapy
10.4.6 Others
10.5 North America Market Value Share Analysis, by Disease Indication
10.6 North America Market Forecast, by Disease Indication
10.6.1 North America Market Forecast, by Hypopigmentation
10.6.1.1 Vitiligo
10.6.1.2 Albinism
10.6.1.3 Others
10.6.2 North America Market Forecast, by Hyperpigmentation
10.6.2.1 Melasma
10.6.2.2 Post-inflammatory Pigmentation
10.6.2.3 Solar Lentigines
10.6.2.4 Others
10.7 North America Market Value Share Analysis, by End-user
10.8 North America Market Forecast, by End-user
10.8.1 Hospitals
10.8.2 Aesthetic Clinics & Dermatology Centers
10.8.3 Others
10.9 Market Analysis, by Country
10.10 Market Value Share Analysis, by Country
10.11 Market Size (US$ Mn) Forecast, by Country, 2018–2026
10.11.1 U.S.
10.11.2 Canada
10.12 Market Attractiveness Analysis
10.12.1 By Treatment
10.12.2 By Disease Indication
10.12.3 By Disease Hypopigmentation
10.12.4 By Disease Hyperpigmentation
10.12.5 By End-user
10.12.6 By Country

Section 11 Europe Pigmentation Disorders Treatment Market Analysis
11.1 Key Findings
11.2 Europe Pigmentation Disorders Treatment Market Overview
11.3 Europe Market Value Share Analysis, by Treatment
11.4 Europe Market Forecast, by Treatment
11.4.1 Topical Drugs
11.4.2 Laser Therapy
11.4.3 Chemical Peels
11.4.4 Microdermabrasion
11.4.5 Phototherapy
11.4.6 Others
11.5 Europe Market Value Share Analysis, by Disease Indication
11.6 Europe Market Forecast, by Disease Indication
11.6.1 Europe Market Forecast, by Hypopigmentation
11.6.1.1 Vitiligo
11.6.1.2 Albinism
11.6.1.3 Others
11.6.2 Europe Market Forecast, by Hyperpigmentation
11.6.2.1 Melasma
11.6.2.2 Post-inflammatory Pigmentation
11.6.2.3 Solar Lentigines
11.6.2.4 Others
11.7 Europe Market Value Share Analysis, by End-user
11.8 Europe Market Forecast, by End-user
11.8.1 Hospitals
11.8.2 Aesthetic Clinics & Dermatology Centers
11.8.3 Others
11.9 Market Analysis, by Country
11.10 Market Value Share Analysis, by Country
11.11 Market Size (US$ Mn) Forecast, by Country, 2018–2026
11.11.1 Germany
11.11.2 France
11.11.3 U.K.
11.11.4 Italy
11.11.5 Spain
11.11.6 Rest of Europe
11.12 Market Attractiveness Analysis
11.12.1 By Treatment Type
11.12.2 By Disease Indication
11.12.3 By Disease Hypopigmentation
11.12.4 By Disease Hyperpigmentation
11.12.5 By End-user
11.12.6 By Country

Section 12 Asia Pacific Pigmentation Disorders Treatment Market Analysis
12.1 Key Findings
12.2 Asia Pacific Pigmentation Disorders Treatment Market Overview
12.3 Asia Pacific Market Value Share Analysis, by Treatment
12.4 Asia Pacific Market Forecast, by Treatment
12.4.1 Topical Drugs
12.4.2 Laser Therapy
12.4.3 Chemical Peels
12.4.4 Microdermabrasion
12.4.5 Phototherapy
12.4.6 Others
12.5 Asia Pacific Market Value Share Analysis, by Disease Indication
12.6 Asia Pacific Market Forecast, by Disease Indication
12.6.1 Asia Pacific Market Forecast, by Hypopigmentation
12.6.1.1 Vitiligo
12.6.1.2 Albinism
12.6.1.3 Others
12.6.2 Asia Pacific Market Forecast, by Hyperpigmentation
12.6.2.1 Melasma
12.6.2.2 Post-inflammatory Pigmentation
12.6.2.3 Solar Lentigines
12.6.2.4 Others
12.7 Asia Pacific Market Value Share Analysis, by End-user
12.8 Asia Pacific Market Forecast, by End-user
12.8.1 Hospitals
12.8.2 Aesthetic Clinics & Dermatology Centers
12.8.3 Others
12.9 Market Analysis, by Country
12.10 Market Value Share Analysis, by Country
12.11 Market Size (US$ Mn) Forecast, by Country, 2018–2026
12.11.1 China
12.11.2 Japan
12.11.3 India
12.11.4 Australia & New Zealand
12.11.5 Rest of Asia Pacific
12.12 Market Attractiveness Analysis
12.12.1 By Treatment
12.12.2 By Disease Indication
12.12.3 By Disease Hypopigmentation
12.12.4 By Disease Hyperpigmentation
12.12.5 By End-user
12.12.6 By Country

Section 13 Latin America Pigmentation Disorders Treatment Market Analysis
13.1 Key Findings
13.2 Latin America Pigmentation Disorders Treatment Market Overview
13.3 Latin America Market Value Share Analysis, by Treatment
13.4 Latin America Market Forecast, by Treatment
13.4.1 Topical Drugs
13.4.2 Laser Therapy
13.4.3 Chemical Peels
13.4.4 Microdermabrasion
13.4.5 Phototherapy
13.4.6 Others
13.5 Latin America Market Value Share Analysis, by Disease Indication
13.6 Latin America Market Forecast, by Disease Indication
13.6.1 Latin America Market Forecast, by Hypopigmentation
13.6.1.1 Vitiligo
13.6.1.2 Albinism
13.6.1.3 Others
13.6.1 Latin America Market Forecast, by Hyperpigmentation
13.6.2.1 Melasma
13.6.2.2 Post-inflammatory Pigmentation
13.6.2.3 Solar Lentigines
13.6.2.4 Others
13.7 Latin America Market Value Share Analysis, by End-user
13.8 Latin America Market Forecast, by End-user
13.8.1 Hospitals
13.8.2 Aesthetic Clinics & Dermatology Centers
13.8.3 Others
13.9 Market Analysis, by Country
13.10 Market Value Share Analysis, by Country
13.11 Market Size (US$ Mn) Forecast, by Country, 2018–2026
13.11.1 Brazil
13.11.2 Mexico
13.11.3 Rest of Latin America
13.12 Market Attractiveness Analysis
13.12.1 By Treatment
13.12.2 By Disease Indication
13.12.3 By Disease Hypopigmentation
13.12.4 By Disease Hyperpigmentation
13.12.5 By End-user
13.12.6 By Country

Section 14 Middle East & Africa Pigmentation Disorders Treatment Market Analysis
14.1 Key Findings
14.2 Middle East & Africa Pigmentation Disorders Treatment Market Overview
14.3 Middle East & Africa Market Value Share Analysis, by Treatment
14.4 Middle East & Africa Market Forecast, by Treatment
14.4.1 Topical Drugs
14.4.2 Laser Therapy
14.4.3 Chemical Peels
14.4.4 Microdermabrasion
14.4.5 Phototherapy
14.4.6 Others
14.5 Middle East & Africa Market Value Share Analysis, by Disease Indication
14.6 Middle East & Africa Market Forecast, by Disease Indication
14.6.1 Middle East & Africa Market Forecast, by Hypopigmentation
14.6.1.1 Vitiligo
14.6.1.2 Albinism
14.6.1.3 Others
14.6.2 Middle East & Africa Market Forecast, by Hyperpigmentation
14.6.2.1 Melasma
14.6.2.2 Post-inflammatory Pigmentation
14.6.2.3 Solar Lentigines
14.6.2.4 Others
14.7 Middle East & Africa Market Value Share Analysis, by End-user
14.8 Middle East & Africa Market Forecast, by End-user
14.8.1 Hospitals
14.8.2 Aesthetic Clinics & Dermatology Centers
14.8.3 Others
14.9 Market Analysis, by Country
14.10 Market Value Share Analysis, by Country
14.11 Market Size (US$ Mn) Forecast, by Country, 2018–2026
14.11.1 GCC Countries
14.11.2 South Africa
14.11.3 Rest of Middle East & Africa
14.12 Market Attractiveness Analysis
14.12.1 By Treatment
14.12.2 By Disease Indication
14.12.3 By Disease Hypopigmentation
14.12.4 By Disease Hyperpigmentation
14.12.5 By End-user
14.12.6 By Country

Section 15 Competition Landscape
15.1 Competition Matrix
15.2 Pigmentation Disorders Treatment Market Share Analysis, by Company (2017)
15.3 Company Profiles
15.3.1 Bayer AG
15.3.1.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2 Product Portfolio
15.3.1.3 SWOT Analysis
15.3.1.4 Strategic Overview
15.3.1.5 Financial Overview
15.3.2 ALLERGAN
15.3.2.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2 Product Portfolio
15.3.2.3 SWOT Analysis
15.3.2.4 Strategic Overview
15.3.2.5 Financial Overview
15.3.3 Galderma S.A. (Nestle Skin Health S.A)
15.3.3.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2 Product Portfolio
15.3.3.3 SWOT Analysis
15.3.3.4 Strategic Overview
15.3.4 SkinCeuticals
15.3.4.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2 Product Portfolio
15.3.4.3 SWOT Analysis
15.3.4.4 Strategic Overview
15.3.5 Pierre Fabre
15.3.5.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2 Product Portfolio
15.3.5.3 SWOT Analysis
15.3.5.4 Strategic Overview
15.3.5.5 Financial Overview
15.3.6 EpiPharm AG
15.3.6.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2 Product Portfolio
15.3.6.3 SWOT Analysis
15.3.6.4 Strategic Overview
15.3.7 RXi Pharmaceuticals Corporation
15.3.7.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2 Product Portfolio
15.3.7.3 SWOT Analysis
15.3.7.4 Strategic Overview
15.3.7.5 Financial Overview
15.3.8 Obagi Cosmeceuticals LLC (Obagi medical)
15.3.8.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2 Product Portfolio
15.3.8.3 SWOT Analysis
15.3.8.4 Strategic Overview
15.3.9 Vivier Pharma
15.3.9.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2 Product Portfolio
15.3.9.3 SWOT Analysis
15.3.9.4 Strategic Overview

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111995/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi